Ligand Pharmaceuticals Inc. operates a royalty-based business model, partnering with major pharmaceutical and biotechnology companies to facilitate drug development. The company's core offering is the Captisol platform, a chemically modified cyclodextrin designed to optimize the solubility and stability of drugs. Ligand's diversified portfolio includes royalty rights to numerous commercialized and in-development pharmaceutical products across therapeutic areas such as oncology, kidney disease, and rare diseases. Notable partnered products from which Ligand receives royalties include the kidney disease therapy Filspari, the pneumococcal vaccine Vaxneuvance, and the multiple myeloma treatments Kyprolis and Evomela. By focusing on licensing and royalties rather than direct commercialization, Ligand maintains a lean operating structure while leveraging the clinical and commercial capabilities of its partners worldwide.
